Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the SARS-CoV-2 spike protein is an envelope glycoprotein that binds angiotensin converting enzyme 2 as an entry receptor.
UCSF School of Medicine and Zuckerberg San Francisco General Hospital
Pulmonary Division, Department of Medicine, Lung Biology Center, and Cardiovascular Research Institute
The Pulmonary Division in the Department of Medicine at Zuckerberg San Francisco General Hospital (ZSFG) and the Cardiovascular Research Institute (CVRI) at the University of California, San Francisco are recruiting an outstanding physician-scientist at the rank of Assistant, Associate, or Full Professor to join the CVRI, Lung Biology Center, and ZSFG Pulmonary Division. The main duties of this position are to maintain an exciting and impactful research program as a member of the CVRI and Lung Biology Center research communities and to attend on the Pulmonary service at Zuckerberg San Francisco General Hospital and be engaged in the teaching of medical students, residents, and pulmonary-critical care fellows.
The successful candidate will be appointed at the Assistant, Associate, or full Professor rank, as appropriate based on experience, in the In Residence Series and will be proposed for faculty membership in UCSF’s Biomedical Sciences and other relevant graduate programs. Permanent partial salary support and laboratory space in the Smith Cardiovascular Research Building on UCSF’s Mission Bay Campus will be provided.
Required qualifications include a medical degree and a medical license with Board Certification/Eligibility in adult Pulmonary and/or Critical Care Medicine, a minimum of four years research experience, and an exciting independent research program relevant to pulmonary or cardiovascular biology. Relevant research areas might include, but are not limited to, genetics, developmental biology, cell and tissue biology, physiology, or patient-based research or epidemiology in pulmonary or cardiovascular diseases. Programs focused on basic, translational, or clinical research will be considered.
Interested candidates must apply online at https://aprecruit.ucsf.edu/JPF03119 with a CV, summaries of research accomplishments (1 page) and future research plans (up to 2 pages), a Statement of Contributions to Diversity (see link in recruitment plan) and contact information for three references. Investigators applying at the Assistant Professor level should arrange for three letters of recommendation to be submitted to the same site. Review of applications will begin on July 1, 2021 and should be submitted prior to that date for full consideration. Contact email@example.com with questions.
UCSF seeks candidates whose experience, teaching, research, or community service has prepared them to contribute to our commitment to diversity and excellence. The University of California is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, age, or protected veteran status.
photo credit to:
In major cardiovascular diseases, including stroke and heart attack, loss of blood flow causes loss of oxygen (ischemia), leading to tissue damage and cell deaths. A species of ground squirrels from the Arctic can tolerate such ischemic attack, but the underlying biological basis has been unknown. The study from this paper led by Neel Singhal from the Ma lab at CVRI identified an unusual protein variant ATP5G1 from cells of Arctic ground squirrels that contributes to the protection from ischemic stress. This basic science discovery may lay the groundwork to develop potential therapeutic strategies to treat human ischemic disorders.
In a clinical collaboration with Melvin Scheinman from the UCSF Comprehensive Genetic Arrythmia Program, CVRI investigators Rahul Deo and Natalia Jura, along with MD/PhD trainee Erron Titus, set out to explain how mutations in the calcium-storage protein, calsequestrin, cause lethal arrhthymias. The team solved a new X-ray crystal structure of human cardiac calsequestrin, revealing the biochemical basis of calsequestrin’s assembly into filaments. Using the new structure, the team was able to map disease-associated mutations to the filament surfaces and explain how the location of the mutation in the structure determines the severity of disease.
The global burden of diabetes is rapidly increasing, from 451 million people in 2019 to 693 million by 20451. The insidious onset of type 2 diabetes delays diagnosis and increases morbidity2. Given the multifactorial vascular effects of diabetes, we hypothesized that smartphone-based photoplethysmography could provide a widely accessible digital biomarker for diabetes. y 20451.
When Dr. Ethan Weiss arrived in New York in late April, he started his first shift almost immediately.
Ethan Weiss, MD is part of the twenty-four UC San Francisco health care workers on voluntary assignment in New York City providing urgently needed health care support for patients.
Pui-Yan Kwok, MD, PhD
This award is to celebrate the achievement of a biomedical scientist:
- who has performed extraordinary work in biomedical sciences which has changed the thinking in the human genomics field; and/or
- who has uncovered new insights which brought forth new therapies; and/or
- whose lifetime contribution has significantly impacted the Asia-Pacific region
It is with great sadness that we share the news that John F. Murray, Professor of Medicine emeritus, has passed away.Dr. Murray was tirelessly dedicated to what was then called San Francisco General Hospital (now, Zuckerberg San Francisco General Hospital & Trauma Center), where he was chief of pulmonology from 1966 until 1989.
Natalia Jura, PhD, is focused on how cells transmit signals via protein molecules on their surface to elucidate what goes wrong in cellular communication with cancer. “We are using cryogenic electron microscopy to tackle the structure of a class of these proteins called Receptor Tyrosine Kinases. These are the first studies that will allow us to look at these molecules as a whole piece, understand their architecture, and see how mutations change them.”
Read the Interview.